FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
(MedPage Today) -- The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma. The approved indication is...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.